ERBB2 and non-small cell lung carcinoma: Currently, HER2 overexpression and activating mutations have been observed in gastric and gastroesophageal cancers [13,14], endometrial cancers [15,16], non-small-cell lung cancers [17,18], and ovarian cancers [19].